Bristol-Myers SquibbBMY
BMY
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
62% more first-time investments, than exits
New positions opened: 264 | Existing positions closed: 163
44% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 26 (+8) [Q3]
21% more capital invested
Capital invested by funds: $64.8B [Q2] → $78.1B (+$13.3B) [Q3]
5% more funds holding
Funds holding: 2,109 [Q2] → 2,210 (+101) [Q3]
6% less call options, than puts
Call options by funds: $1.88B | Put options by funds: $1.99B
2.39% less ownership
Funds ownership: 76.92% [Q2] → 74.53% (-2.39%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 802 | Existing positions reduced: 904
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$39
32%
downside
Avg. target
$57
0%
upside
High target
$73
27%
upside
11 analyst ratings
2 positive
18%
7 neutral
64%
2 negative
18%
Jefferies Akash Tewari 23% 1-year accuracy 3 / 13 met price target | 22%upside $70 | Buy Upgraded | 16 Dec 2024 |
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 10%upside $63 | Neutral Reinstated | 10 Dec 2024 |
Citigroup Andrew Baum 25% 1-year accuracy 1 / 4 met price target | 5%upside $60 | Neutral Maintained | 12 Nov 2024 |
BMO Capital Evan Seigerman 50% 1-year accuracy 8 / 16 met price target | 6%upside $61 | Market Perform Maintained | 12 Nov 2024 |
Morgan Stanley Terence Flynn 25% 1-year accuracy 4 / 16 met price target | 32%downside $39 | Underweight Maintained | 12 Nov 2024 |
Financial journalist opinion
Based on 38 articles about BMY published over the past 30 days
Positive
The Motley Fool
8 hours ago
Want Decades of Passive Income? 3 Stocks to Buy Right Now
Are you looking for reliable long-term investment income? Consider starting your search here, with a closer look at three great dividend stocks that would be at home in nearly any investor's portfolio.
Positive
Seeking Alpha
23 hours ago
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects
BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired schizophrenia therapy. These build upon the 8 new oncology registrational trials added in past year, as the management seeks to deliver new growth opportunities in the face of upcoming patent cliff. These developments also lend strength to BMY's Growth portfolio outperformance by +20% YoY, with the growth-to-legacy portfolio ratio increasingly skewed to the former at 48.7%.
Positive
Seeking Alpha
1 day ago
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but has promising new drugs like Cobenfy to offset potential revenue declines. Recent quarterly results show solid revenue growth, though earnings per share have declined, and management has raised revenue guidance for the fiscal year.
Neutral
Zacks Investment Research
1 day ago
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.30, moving -0.95% from the previous trading session.
Positive
The Motley Fool
2 days ago
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio.
Neutral
Business Wire
2 days ago
Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer
MIDDLETON, Wis.--(BUSINESS WIRE)-- #HealthtechInnovation--Imbed Biosciences today announced that Terry Bromley has joined as Chief Executive Officer. With over 30 years of experience in the medical device, regenerative medicine and wound and skin markets, Mr. Bromley will be instrumental in fostering the company's growth and continue Imbed Biosciences' mission to transform the future of soft tissue repair through advanced technologies focused on improving patient outcomes. “Terry brings a wealth of commercial leadersh.
Neutral
Business Wire
2 days ago
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025.
Positive
The Motley Fool
2 days ago
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy.
Positive
The Motley Fool
2 days ago
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast amounts of capital.
Neutral
PRNewsWire
2 days ago
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
STOCKHOLM , Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's BrainTransporter™ technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments.
Charts implemented using Lightweight Charts™